PEGASUS (NCT03533257) was a Phase 2a, randomized, placebo-controlled trial in 95 participants in the U.S. evaluating safety, tolerability, neurobiological activity, and preliminary clinical efficacy of AMX0035 in a broad range of participants with early dementia or late mild cognitive impairment due to Alzheimer’s disease.
The PEGASUS trial has completed and top line results were presented in November 2021. Read more details in this press release (opens new window).